BioNTech

BNTXPhase 3

BioNTech SE is a publicly-traded immunotherapy powerhouse founded by scientists and physicians to translate science into survival through innovative mRNA technologies. The company gained global recognition for its COVID-19 vaccine developed with Pfizer and is now applying its mRNA expertise to cancer immunotherapies and other infectious diseases. With over 25 Phase 2 and Phase 3 oncology trials and a €2.10 billion R&D investment planned for 2025, BioNTech is positioning itself as a leader in personalized cancer treatment and next-generation vaccines.

Market Cap

$22.4B

Employees

3,000-5,000

Focus

BiologicsRNA & Gene TherapyCell & Gene Therapy

BNTX · Stock Price

USD 89.2771.83 (-44.59%)

Historical price data

AI Company Overview

Technology Platform

mRNA technology platform for developing personalized cancer immunotherapies, next-generation immunomodulators, and vaccines against infectious diseases. The platform enables rapid development of individualized treatments and has been validated through successful COVID-19 vaccine commercialization.

Pipeline Snapshot

73 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
Gotistobart + Docetaxel	Non Small Cell Lung Cancer	Phase 3
DB-1303/BNT323 + Capecitabine + Paclitaxel + Nab-paclitaxel	Metastatic Breast Cancer	Phase 3
BNT323/DB-1303 + Doxorubicin + Paclitaxel + Docetaxel	Endometrial Cancer	Phase 3
DB-1303/BNT323 + T-DM1	HER2-positive Breast Cancer	Phase 3
BNT324 + Docetaxel + Prednisone/prednisolone	Metastatic Castration-resistant Prostate Cancer	Phase 3

Funding History

Total raised: $420M

IPO$150MUndisclosedOct 10, 2019

Series A$270MMIG AGJan 15, 2018

Opportunities

Massive market opportunity in personalized cancer medicine with validated mRNA platform.

Strong financial position enables aggressive R&D investment across multiple high-potential programs.

Proven ability to execute complex global programs provides competitive advantage.

Risk Factors

Heavy dependence on COVID-19 vaccine revenues as pandemic normalizes.

Clinical execution risk across ambitious oncology pipeline.

Intense competition in mRNA therapeutics space with well-funded competitors.

Competitive Landscape

Competes with Moderna in mRNA technology, major pharma companies like Merck and Bristol Myers Squibb in cancer immunotherapy, and emerging personalized vaccine companies. Differentiated by proven commercial mRNA platform and focus on personalized medicine approaches.

Publications

Patents

Pipeline